MyCelx Technologies Corporation Grant of Share Options to Chief Financial Officer
18 Março 2024 - 4:00AM
RNS Regulatory News
RNS Number : 1413H
MyCelx Technologies Corporation
18 March 2024
18 March 2024
MYCELX
Technologies Corporation
("MYCELX"
or the "Company") (AIM: MYX)
Grant of Share Options to
Chief Financial Officer
On 15 March 2024 Ms. Slayton, a PDMR
of the Company, was awarded the following options over the
Company's common shares of US$0.025 each ("Common Shares") under
the MYCELX Omnibus Performance Incentive Plan ("Plan"):
|
Name of
PDMR
|
Number of share options
granted
|
Exercise
price
|
Total number of share options
held following this notification
|
Total number of share options
as % of current issued share capital
|
|
|
|
|
|
|
|
Kimberly
Slayton
|
50,000
|
US$0.59
|
313,334
|
1.36%
|
Ms. Slayton holds no Common Shares
in the issued capital of the Company.
The share options granted to
Kimberly Slayton on 15 March 2024 will vest as to 50% on 31
December 2024 and 50% on 31 December 2025. The exercise price was
based on the mid-market closing price of the Company's Common
Shares at 15 March 2024, and the closing US/£ exchange rate at that
date.
The above grant is included as part
of wider grants of 300,000 options in aggregate to employees across
the Company on 13 March 2024 and 15 March 2024, representing 1.31%
of the current issued share capital. All of
the options must be exercised prior to the tenth anniversary of the
date of grant, subject to the restrictions on dealing under the
Company's share dealing code.
Details of the transaction are
reported in the PDMR notification below:
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Kimberly Slayton
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Financial Officer
|
|
b)
|
Initial notification/Amendment
|
Initial Notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
MYCELX Technologies
Corporation
|
|
b)
|
LEI
|
213800UJZINIK2VD1G48
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type of
instrument
|
Grant of options over 50,000 common
shares of US$0.025 each.
ISIN: US62847T2024
|
|
c)
|
Currency
|
US$
|
|
d)
|
Price(s) and volumes(s)
|
Price(s)
|
Volume(s)
|
|
|
|
US$0.59
|
50,000
|
|
e)
|
Aggregated information
- Aggregated
volume
- Price
|
As above
|
|
f)
|
Date of the transaction
|
15 March 2024
|
|
g)
|
Place of the transaction
|
NA (grant of options)
|
For
further information, please contact:
|
MYCELX Technologies Corporation
Connie Mixon, CEO
Kim Slayton, CFO
|
Tel: +1 888 306 6843
|
|
Canaccord Genuity Limited (Nomad and Sole
Broker)
Henry Fitzgerald-O'Connor
Ana Ercegovic
|
Tel: +44 20 7523 8000
|
|
Celicourt Communications (Financial PR)
Mark Antelme
Jimmy Lea
Charlie Denley-Myerson
|
Tel: +44 20 7770 6424
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHKZGMFKNLGDZM
Mycelx Technologies (LSE:MYX)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Mycelx Technologies (LSE:MYX)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024
